Maravai LifeSciences Bolsa (NASDAQ: MRVI)

Últimas noticias sobre Maravai LifeSciences (NASDAQ:MRVI) Bolsa

Maravai LifeSciences

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences Holdings Inc

Kratos Defense &amp; Security Solutions, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>), a&nbsp;Technology Company&nbsp;in the Defense, National Security and Global Markets,&nbsp;and GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) today announced a formal teaming agreement to advance propulsion technologies for the next generation of affordable unmanned aerial systems and Collaborative Combat Aircraft-type (CCA-type) aircraft.
Eric DeMarco, President and CEO of Kratos, said, "Kratos' strategically important Teaming Agreement with GE Aerospace continues to rapidly advance and expand, with the GEK family of engines targeting certain of the most important, mission critical and highest priority needs and requirements of United States National Security. At Kratos, affordability is a technology and delivering more capability for less cost as quickly as possible are key contributions we are bringing for truly industry leading GEK offerings with our partner and global leader GE Aerospace."
"The formalization of this teaming agreement and initiation of development of these new engines mark another step forward in our dedication to providing affordable, adaptable, high-performance propulsion systems for the future force," said Amy Gowder, President and CEO of Defense &amp; Systems at GE Aerospace. "We're thrilled to continue our collaboration with Kratos and accelerate development across various classes of unmanned systems."
This collaboration strengthens Kratos' ongoing partnership with GE Aerospace – building on last year's Memorandum of Understanding (MOU) to advance the development and production of small, cost-effective engines for unmanned platforms. The new teaming agreement expands on that MOU and provides the framework for the two companies to develop, manufacture, test, and field the GEK800 Engine, as well as collaborate on other low-cost expendable turbofan engines.

News

Contracts

KTOS

Kratos And GE Aerospace Enters Partnership To Advance Propulsion Technologies For Next Generation Of Affordable Unmanned Aerial Systems And Collaborative Combat Aircraft-Type Aircraft

QMCO

Quantum Appoints Hugues Meyrath As CEO, Succeeding Jamie Lerner, Effective June 2

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001's Ability to Recruit a Powerful Anti-Cancer Immune Response&nbsp;
Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed Gynecologic Oncology, suggest very meaningful survival effect of IMNN-001 in women HRP and HRD positive, including those with BRAC1 and BRCA2 mutations
LAWRENCEVILLE, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=ttxBJzPL1rX9mmte31uKToC6Ztc4cmAPidqr360A89EvH2jeIzQ54mHWOYtk_ZuyE1LXXi_yIEi7_Mfnh9hA4OCMjmB4DTc0mwZGPjJZaCF-Y5Kj-yh19-uirljg0cwcpq7CGuodNrt_EaMLrXEUXZlwhwf0vnYToWYwku78OPXu6_33bwtS_sF6Yq35qFjx1cABTzYh0s-dQdtbrpffdOd5WXriZrM-qL6rFs9goReLErw1ux5_Up3k0BAjPmBZ3jt3ONenlErsvnDhrFrd1HCQ4XBYY_MmQyKWqn6OjAj056vYuL0AbT1kA-p__M-5Y5Jf_blVAMBrjwI_Zrsvq1yI1QR5rVSf_UZ7hIgixvo=">IMUNON</a>, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced positive data from the Company's Phase 2 OVATION 2 Study showing that treatment with IMNN-001 in women with newly diagnosed advanced ovarian cancer resulted in consistent, clinically meaningful improvements in several key endpoints across treatment groups, including overall survival (OS), progression-free survival (PFS), chemotherapy response score and surgical response. Treatment with IMNN-001 also showed a favorable safety profile, with no reports of serious immune-related adverse events. The full results are being presented today in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, and simultaneously published in the peer-reviewed journal Gynecologic Oncology.
Participants with newly diagnosed advanced epithelial ovarian cancer in the Phase 2 OVATION 2 Study (n=112) were randomized 1:1 to evaluate the safety and efficacy of IMNN-001 (100 mg/m2 administered intraperitoneally weekly) plus neoadjuvant and adjuvant chemotherapy (N/ACT) compared to standard of care (SoC) N/ACT alone, with a median follow-up of 31 months. The data being presented today highlight the consistent results achieved across all treatment groups, demonstrating:
<ul>
<li>Median 13-month increase in OS (46 vs. 33 months) and median 3-month increase in PFS (14.9 vs. 11.9 months) in IMNN-001 treatment arm compared to standard of care alone.</li>
<li>Better therapeutic effect observed with IMNN-001 treatment compared to the control arm (p=0.0375), as shown by mean 6.5-month extension of time free of progression or death (PFS + OS) captured in totality of treatment effect.</li>
<li>Use of poly ADP-ribose polymerase (PARP) inhibitors as part of maintenance therapy further enhanced outcomes, with median OS not yet reached in IMNN-001 treatment arm after &gt;5 years compared to 37 months on standard of care.</li>
<li>Chemotherapy response score highlights double the response rate of a complete or near complete histopathological response following treatment with 26.1% in the IMNN-001 treatment arm compared to 13.0% in the control arm.</li>
<li>Surgical response rate of no macroscopic residual tumor left after surgery 64.6% in the IMNN-001 treatment arm compared to 52.1% in the control arm.</li>
<li>Hazard ratio of 0.78 in study participants who are homologous recombination proficient (HRP) and hazard ratio of 0.42 in women positive for homologous recombination deficiency (HRD+), including BRCA1 or BRCA2 mutations, suggesting increased therapeutic activity.</li>
<li>IMNN-001 was generally safe and well tolerated, with no reports of cytokine release syndrome, systemic toxicity or serious immune-related adverse events (AEs). The most common AEs primarily included abdominal pain, nausea and vomiting.</li>
</ul>

Biotech

General

IMNN

IMUNON's IMNN-001 Shows Overall Survival Benefit Across Ovarian Cancer Subgroups In Phase 2 OVATION 2 Study, With Gains In HRP And BRCA+ Patients, Favorable Safety Profile, And Simultaneous ASCO 2025 And Peer-Reviewed Publication Presentation In Gynecologic Oncology

JP Morgan analyst Eric Joseph maintains Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) with a Overweight and raises the price target from $57 to $64.

Price Target

Analyst Ratings

KYMR

JP Morgan Maintains Overweight on Kymera Therapeutics, Raises Price Target to $64

WIIM

MLTX

MoonLake Immunotherapeutics shares are trading higher following reports that Merck is looking to acquire the company in a deal valued at over $3 billion.

Recycling feedstock such as EV motors, HDDs, wind turbines, MRI machines, and other permanent magnet-containing materials scaling to 2,000+ metric tons per annum
The partnership brings together two companies from two nations that are dedicated to developing cost effective domestic supply chains for critical minerals and rare earth elements
FISHERS, IN / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 3, 2025 / American Resources Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) ("American Resources"), through its holding in ReElement Technologies Corporation ("ReElement" or "RTC"), a leading U.S. innovator in rare earth element (REE) and critical mineral refining, announced today that it has signed a memorandum of understanding (MOU) to enter into a joint venture agreement with Exigo Battery Solutions Pvt. Ltd. ("Exigo") to have the joint venture entity utilize ReElement's proprietary rare earth oxide refining technologies within the United States and in India along with Exigo's ability to source, process, and supply rare earth concentrates to be efficiently and cost effectively refined to separated and purified 99.5%+ oxides (NdPr, Nd, Dy, Tb). The goal of the joint venture is to grow the partnership to 2,000 metric tons or greater per year as part of the joint venture commercial relationship.
Exigo will initially supply rare earth concentrates to ReElement's Marion, Indiana facility to be refined to magnet grade oxides, with the goal of expanding thereafter by deploying ReElement's technology to India to refine such rare earth elements.

AREC

American Resources Signs MOU To Enter Into JV Agreement With Exigo Battery Solutions For Rare Earth Magnet Recycling

Business Outlook For the second quarter of 2025, the Company expects:
<ul>
<li>Deliveries of vehicles&nbsp;to be between 72,000 and 75,000 vehicles, representing an increase of approximately 25.5% to an increase of approximately 30.7% from the same quarter of 2024.</li>
<li>Total revenues&nbsp;to be between RMB19,513&nbsp;million (US$2,689 million) and RMB20,068 million (US$2,765 million), representing an increase of approximately 11.8% to an increase of approximately 15.0% from the same quarter of 2024.</li>
</ul>

Guidance

NIO Expects Q2 Vehicle Deliveries Of 72K-75K, Up By 25.5%-30.7% YoY

Events

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

Jasper Therapeutics Pressnts Briquilimab Aat EAACI Annual Congress

Skyward Specialty Insurance Group, Inc.TM&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKWD#NASDAQ">SKWD</a>) ("Skyward Specialty" or "the Company") a leader in the specialty property and casualty (P&amp;C) market, announced its entry into the specialized aviation market with the launch of a new Aviation underwriting unit. The expansion follows the Company's acquisition of the assets of Acceleration Aviation Underwriters ("Acceleration") and builds on a strategic partnership between the two companies initiated last year.
This move marks a bold step forward in the Company's ongoing growth strategy, leveraging technology and data-driven underwriting to expand into highly specialized and underserved markets.

SKWD

Skyward Specialty Insurance Enters Specialized Aviation Market With Launch Of New Aviation Underwriting Unit

Blink Charging Co. ("Blink"), a leading owner, operator, provider and manufacturer of electric vehicle (EV) charging equipment and services, has announced a collaboration with <a href="https://www.globenewswire.com/Tracker?data=Xiy8xO6N3Z8EoKZIPRwqDpM9kWqK0bBFVmamAkQ9U1L7BTNGH926X96eTw0skqYKxbCdNTTfpqMaFiQRLSkA7xd_Yl7kfmFWQZTxixGAi7A=">WirelessCar</a> Sweden AB ("WirelessCar"), a global leader in connected vehicle services, and <a href="https://www.globenewswire.com/Tracker?data=o0jdc34BMwtz-VJmUpbAqEeDrRm5JqcIdnXIvhwbvfTeYz7KB9LBieIDv_lNWJYaA6DXuE8pBTFRwHd4d0sa2g==">ChargeHub</a>, North America's leading EV roaming hub, to launch an innovative ‘Seamless Charging' pilot program in the United States and Canada. This ground-breaking initiative is designed to redefine the EV charging experience, making it faster, easier, and more accessible for drivers.
For those without easy access to EV charging infrastructure, using an EV may seem complicated. The many apps, tags and cards designed to simplify the process may actually deter new users, especially if they make charging less convenient than refuelling an internal combustion engine (ICE) vehicle.
The ‘Seamless Charging' initiative eliminates common barriers to EV charging through a simple, single-app signup. By leveraging an advanced connected services feature, EV drivers can plug into Blink chargers without needing to log into multiple apps or manage various accounts. After a one-time registration with the ChargeHub app and activation of Seamless Charging, drivers will simply plug in at any Blink Charging Station, and walk away.
Powered by connected vehicle data and real time events, Seamless Charging is a WirelessCar innovation that streamlines public charging, particularly for drivers without access to home charging. The solution utilizes information shared by both the vehicle and charging provider. When the EV is plugged in, the driver is notified that charging has started—automatically and without cards, apps, or additional steps. The result is a radically more convenient EV charging experience, powered by connectivity.
"We're thrilled to collaborate with WirelessCar and ChargeHub to bring the innovative 'Seamless Charging' pilot concept to North America," said Mike Battaglia, President and CEO of Blink. "This project is about improving accessibility and convenience for EV drivers, ensuring a smooth transition to electric mobility."
Niklas Florén, CEO of WirelessCar, added, "At WirelessCar, we're committed to making the connected vehicle experience effortless and intuitive. Seamless Charging is a powerful example of how we turn vehicle data into everyday convenience—by removing friction from public EV charging. We're proud to collaborate with Blink and ChargeHub to bring this innovation to EV drivers across North America."
Simon Ouellette, CEO of ChargeHub added "Our mission at ChargeHub is to help drivers find and seamlessly pay at charging stations. We connect every part of the EV ecosystem to make this a reality. We're excited to collaborate with WirelessCar and Blink on the innovative 'Seamless Charging' pilot concept in North America."

BLNK

Blink Charging, WirelessCar, And ChargeHub Enters Collaboration To Launch A Seamless Charging Pilot Program Across North America

PINS

Pinterest shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $35 to $40.

—New Patents Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclerosing Cholangitis Issued in China and Russia Providing Coverage Up To 2041—
—Further Expands Protections Provided by Nebokitug's Composition of Matter and Methods and Use Patents Issued in the U.S., Europe, Japan and Additional Key Territories—
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Sg-DggCESWn_rzY2JziwkYkz6ioEIxa7wDjDUtEOWTRMsoxvKoOQo1q9IMmJDPoTvDSPNaOVv1GwQCqldLSzYjdPK9EW-8ZhnSizADda3noWqyL6yWPJ6HORoF_QBLYl">Chemomab Therapeutics, Ltd</a>., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that its lead product nebokitug (formerly CM-101) has been awarded new patent protections in China and Russia.
Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab, commented, "These newly granted patents further strengthen the company's extensive intellectual property portfolio for nebokitug, reinforcing its leading strategic position in primary sclerosing cholangitis (PSC) established by the positive data from the nebokitug Phase 2 SPRING trial, which we believe represents the most promising clinical results to date in this debilitating and potentially lethal disease that lacks effective treatment. Furthermore, for the first time the FDA has aligned on a clear and straightforward pathway to regulatory approval in PSC. We have amassed a large and comprehensive intellectual property portfolio for nebokitug and are pleased to add these new patents in China and Russia, two significant territories for future commercialization. Enlarging the scope of our patent protections is especially relevant as we continue to advance potential partnerships to support a nebokitug Phase 3 registrational trial in PSC."
The State Intellectual Property Office of the People's Republic of China has issued Patent No. ZL 2018 8 0018207.8, Anti-CCL24 (Eotaxin 2) Antibodies for Use in the Treatment of Hepatic Disease. This patent protects the usage of nebokitug in hepatic diseases, including primary sclerosing cholangitis, and provides coverage through 2038.
The Federal Service for Intellectual Property of the Russian Federation issued RU Patent 2022125176, A Method of Treatment Using Anti-CCL24 Antibodies. This patent protects the usage of different formulations and doses of nebokitug and provides coverage through 2041.

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

Chemomab Therapeutics' Lead Product Nebokitug Awarded New Patent Protections In China And Russia

Village Super Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLGEA#NASDAQ">VLGEA</a>) reported quarterly earnings of $0.75 per share. This is a 25 percent increase over earnings of $0.60 per share from the same period last year. The company reported $563.67 million in sales this quarter. This is a 3.16 percent increase over sales of $546.40 million the same period last year.

Earnings

VLGEA

Village Super Market Q3 EPS $0.75 Up From $0.60 YoY, Sales $563.67M Up From $546.40M YoY

CORRECTION: NIO Sees Q2 Sales $2.689B-$2.765B vs $2.78B Est

The Oncology Institute To Join Russell 2000 And Russell 3000 Indexes

<ul>
<li>Aim to enable fast, clean, quiet and affordable commercial passenger transportation in Saudi Arabia</li>
<li>Potential delivery of up to 200 electric aircraft and related services valued at approximately $1 billion over coming years</li>
<li>Grounded in Saudi Arabia's Vision 2030, new MOU to support socio-economic growth in the Kingdom</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Falj.com%2Fen%2F&amp;esheet=54264111&amp;newsitemid=20250603862191&amp;lan=en-US&amp;anchor=Abdul+Latif+Jameel&amp;index=1&amp;md5=294bb53caf3452c89cc0a4d7f104badf">Abdul Latif Jameel</a>, an 80 year-old network of diversified businesses, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.jobyaviation.com%2F&amp;esheet=54264111&amp;newsitemid=20250603862191&amp;lan=en-US&amp;anchor=Joby+Aviation%2C+Inc.&amp;index=2&amp;md5=cb03f1d0e96ed6476483360f469417c3">Joby Aviation, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>), a company developing electric air taxis for commercial passenger service, are announcing the signing of a Memorandum of Understanding (MoU) to explore opportunities to establish a distribution agreement in Saudi Arabia for Joby's electric aircraft. This announcement builds upon the renewed economic partnership between the U.S. administration and the Saudi government towards shared innovation and transportation growth. Potential delivery of up to 200 Joby aircraft and related services valued at approximately $1 billion are expected by the businesses over the coming years. In the long-term, Abdul Latif Jameel and Joby also see potential revenue opportunities across the Middle East.
Abdul Latif Jameel and Joby share complementary long-term visions to revolutionize the future of mobility through transportation services that are cleaner, safer, more efficient and more affordable, helping to improve passenger experiences while simultaneously protecting the planet. In addition, the Jameel family invested in Joby's Series C funding round, led by Toyota Motor Corporation in 2020.
The direct sale of aircraft through businesses such as Abdul Latif Jameel form one pillar of Joby's commercialization strategy. Additionally, Joby will directly own and operate its aircraft and services in certain markets, like the United States, and partner for similar operations in other markets, such as Japan.

JOBY

Abdul Latif Jameel And Joby Aviation Sign Mou To Explore Opportunities To Establish Distribution Agreement In Saudi Arabia For Joby's Electric Aircraft

APLD

CRWV

CoreWeave and Applied Digital shares are trading higher on possible continued strength following its data center deal announced yesterday.

<h3>Gainers</h3>
<ul>
<li>Citi Trends (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRN#NASDAQ">CTRN</a>) shares increased by 14.4% to $30.9 during Tuesday's pre-market session. The market value of their outstanding shares is at $255.7 million. As per the news, the Q1 earnings report came out today. </li>
<li>Signet Jewelers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) shares moved upwards by 12.85% to $75.4. The company's market cap stands at $3.1 billion. As per the press release, Q1 earnings came out today. </li>
<li>Greenlane Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) stock increased by 11.47% to $0.01. The company's market cap stands at $6.9 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) shares increased by 7.34% to $3.8. The company's market cap stands at $30.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) shares fell 9.7% to $0.31 during Tuesday's pre-market session. The market value of their outstanding shares is at $10.8 million. </li>
<li>Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) stock fell 8.34% to $1.1. The company's market cap stands at $117.2 million. </li>
<li>Yoshiharu Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YOSH#NASDAQ">YOSH</a>) stock fell 8.03% to $14.55. The market value of their outstanding shares is at $25.6 million. </li>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) stock declined by 5.42% to $52.37. The company's market cap stands at $36.5 million. </li>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) stock decreased by 5.38% to $1.76. The market value of their outstanding shares is at $503.6 million. </li>
<li>Lazydays Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) stock decreased by 5.19% to $0.27. The company's market cap stands at $29.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CHGG

CTRN

ECDA

GNLN

GORV

NWTN

QVCGA

SBET

YOSH

10 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Rekor Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REKR#NASDAQ">REKR</a>) stock increased by 20.9% to $1.33 during Tuesday's pre-market session. The company's market cap stands at $157.0 million. </li>
<li>Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) stock rose 15.55% to $72.4. The market value of their outstanding shares is at $12.1 billion. As per the news, the Q4 earnings report came out yesterday. </li>
<li>X3 Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) stock increased by 10.96% to $1.51. The company's market cap stands at $20.7 million. </li>
<li>Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) shares moved upwards by 9.45% to $0.38. The market value of their outstanding shares is at $10.8 million. </li>
<li>Argo Blockchain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) stock moved upwards by 8.66% to $0.38. The market value of their outstanding shares is at $24.1 million. </li>
<li>Tungray Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRSG#NASDAQ">TRSG</a>) shares moved upwards by 7.52% to $1.87. The market value of their outstanding shares is at $30.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) stock decreased by 14.3% to $0.42 during Tuesday's pre-market session. The company's market cap stands at $17.3 million. </li>
<li>Marin Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) shares decreased by 5.53% to $0.74. The market value of their outstanding shares is at $2.3 million. </li>
<li>Hitek Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HKIT#NASDAQ">HKIT</a>) shares fell 4.52% to $1.48. The market value of their outstanding shares is at $43.3 million. </li>
<li>HeartCore Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCR#NASDAQ">HTCR</a>) stock declined by 3.66% to $0.58. The company's market cap stands at $12.8 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARBK

BNAI

CMBM

CRDO

HKIT

HTCR

MRIN

REKR

TRSG

XTKG

10 Information Technology Stocks Moving In Tuesday's Pre-Market Session

VSCO

Victoria's Secret & Co Sees Q1 2025 Net Sales $1.3B-$1.33B; Sees Adj. EPS $(0.10)-$0.10

Legal

Press Releases

MRVI DEADLINE TODAY: Maravai LifeSciences (MRVI) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Maravai LifeSciences

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Maravai LifeSciences Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRVI

Penny Stocks

Small Cap

MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Investors who lost money on Maravai LifeSciences Holdings, Inc.(MRVI) should contact Levi & Korsinsky about pending Class Action - MRVI

Maravai Lifesciences Reports First Quarter 2025 Financial Results

TriLink BioTechnologies® and the International Vaccine Institute Sign a Memorandum of Understanding to Support the Development of mRNA-based Vaccines

TriLink BioTechnologies® debuts its first mRNA synthesis kit with CleanCap® capping technology; Celebrates launch with kit donations to top academic institutions

Maravai LifeSciencesReleases 2024 Sustainability Report

CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report

MRVI

AbCellera Biologics

Atlantic International Corp. - Common Stock

Atlantic International

Azenta

BioLife Solutions

Codexis

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Maravai LifeSciences

Noticias

Últimas noticias sobre Maravai LifeSciences (NASDAQ:MRVI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL